[ ¹⁷⁷ Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

Autor: Singh S; University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada. Electronic address: simron.singh@sunnybrook.ca., Halperin D; MD Anderson Cancer Center, Houston, TX, USA., Myrehaug S; University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada., Herrmann K; Department of Nuclear Medicine, University of Duisburg-Essen, and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; National Center for Tumor Diseases (NCT), NCT West, Heidelberg, Germany., Pavel M; Department of Medicine 1, Uniklinikum Erlangen, and Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Kunz PL; Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA., Chasen B; MD Anderson Cancer Center, Houston, TX, USA., Tafuto S; Sarcoma and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Naples, Italy., Lastoria S; Division of Nuclear Medicine, Istituto Nazionale Tumori IRCCS, Fondazione G Pascale, Naples, Italy., Capdevila J; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., García-Burillo A; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, South Korea., Yoo C; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Halfdanarson TR; Mayo Clinic, Rochester, MN, USA., Falk S; Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, UK., Folitar I; Novartis Pharma AG, Basel, Switzerland., Zhang Y; Novartis Pharmaceuticals Corp, East Hanover, NJ, USA., Aimone P; Novartis Pharma AG, Basel, Switzerland., de Herder WW; Erasmus MC and Erasmus MC Cancer Institute, Rotterdam, Netherlands., Ferone D; Endocrinology, IRCCS Policlinico San Martino and DiMI, University of Genova, Genoa, Italy.

Publikováno v: Lancet (London, England) [Lancet] 2024 Jun 29; Vol. 403 (10446), pp. 2807-2817. Date of Electronic Publication: 2024 Jun 05.

1148MO A multivariate efficacy analysis of [177Lu]Lu-DOTA-TATE in the NETTER 2 study

Autor: Pavel, M.E., Ferone, D., Halperin, D., Myrehaug, S., Herrmann, K., Kunz, P.L., Chasen, B., Capdevila Castillon, J., Tafuto, S., Oh, D-Y., Yoo, C., Falk, S., Halfdanarson, T.R., Folitar, I., Zhang, Y., de Herder, W.W., Singh, S.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S753-S753

Efficacy and Safety of [ ¹⁷⁷ Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review.

Autor: Hertelendi M; Advanced Accelerator Applications International SA, 4 Rue de la Tour de l'Ile, 1204 Geneva, Switzerland., Belguenani O; Advanced Accelerator Applications International SA, 4 Rue de la Tour de l'Ile, 1204 Geneva, Switzerland., Cherfi A; Novartis Pharma AG, 4002 Basel, Switzerland., Folitar I; Novartis Pharma AG, 4002 Basel, Switzerland., Kollar G; Advanced Accelerator Applications International SA, 4 Rue de la Tour de l'Ile, 1204 Geneva, Switzerland., Polack BD; Novartis Pharmaceuticals, One Health Plaza, East Hanover, NJ 07936-1080, USA.

Publikováno v: Biomedicines [Biomedicines] 2023 Mar 27; Vol. 11 (4). Date of Electronic Publication: 2023 Mar 27.

Efficacy and safety of ¹⁷⁷ Lu‑DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study.

Autor: Clement D; King's College Hospital, London, UK. dominique.clement@nhs.net., Navalkissoor S; Royal Free Hospital, London, UK., Srirajaskanthan R; King's College Hospital, London, UK., Courbon F; Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France., Dierickx L; Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France., Eccles A; Guy's and St Thomas' Hospital, London, UK., Lewington V; Guy's and St Thomas' Hospital, London, UK., Mitjavila M; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Percovich JC; Hospital General Universitario Gregorio Marañón, Madrid, Spain., Lequoy B; Novartis Pharma AG, Basel, Switzerland., He B; Novartis Pharma AG, Basel, Switzerland., Folitar I; Novartis Pharma AG, Basel, Switzerland., Ramage J; King's College Hospital, London, UK.

Publikováno v: European journal of nuclear medicine and molecular imaging [Eur J Nucl Med Mol Imaging] 2022 Aug; Vol. 49 (10), pp. 3529-3537. Date of Electronic Publication: 2022 Apr 07.

1122TiP A phase II trial to evaluate the safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), pheochromocytomas and paragangliomas (PPGLs)

Autor: Gaze, M.N., O'Dorisio, M.S., Sábado, C., Brouri, F., Folitar, I.

Publikováno v: In Annals of Oncology September 2021 32 Supplement 5:S920-S920